A Prospective Low-Interventional Phase 4 Single Arm Study of Ocular Assessments in Patients Treated with Tivdak® in Recurrent or Metastatic Cervical Cancer

Status: Recruiting

Eligibility Criteria

Sex: Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- cervical cancer that has returned (recurrent) or spread to other parts of the body (metastasized) during or after chemotherapy - doctor has decided that Tivdak® is an option for treatment - agree to use effective contraception

Exclusion Criteria:

- active eye disease - women who are breastfeeding, pregnant, or planning to become pregnant

Conditions & Interventions

Interventions:
Drug: TIVDAK
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), cervical cancer

More Information

Description: The purpose of this study is to learn more about ocular (relating to the eye) side-effects of tisotumab vedotin (brand name: TIVDAK™). A side effect is anything the drug does to your body besides treating your disease. It is approved for women with cervical cancer that has spread through the body or come back during or after chemotherapy. We are doing a study to understand whether there are any ocular side-effects of TIVDAK.
Study Contact: Alyssa Pecoraro - pecor029@umn.edu
Principal Investigator: Deanna Teoh
Phase: PHASE4
IRB Number: STUDY00025592